Downstream Processing Featured Articles

  1. New Epoch 2 Provides Enhanced User Interface For Spectral Absorbance Detection 7/2/2014

    BioTek proudly unveils the new Epoch™ 2 Microplate Spectrophotometer. Epoch 2 is the first reader to combine a large touchscreen and full onboard data analysis software for simplified and efficient operation and reporting of absorbance-based detection workflows.

  2. FDA Approves New Combination Vaccine That Protects Children Against Two Bacterial Diseases 6/14/2012

    The U.S. Food and Drug Administration recently approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b.

  3. 3M Launches Large-Scale, Single-Use, Multi-Round Depth Filtration System 6/14/2012

    3M expanded its portfolio of Encapsulated Zeta Plus™ single-use depth filtration products to include our Model# 16EZC Multi-Round Holder.

  4. Revision Of The EU GMP Guide: EU Commission Publishes Proposals For Chapters 3, 5, 6 And 8 1/24/2013

    On 17 January 2013, the EU Commission published the drafts of 4 revised chapters of the EU GMP Guide. The publication had been expected for a long time now.

  5. Forsyth Scientists Define The Bacteria That Live In The Mouth, Throat, And Gut 9/20/2012

    For the first time, scientists have defined the bacteria that inhabit multiple sites along the healthy human digestive tract in a large number of individuals. To prevent and control bacterial diseases, it is essential to first identify which bacteria are responsible for keeping us in good health.

  6. Unraveling The Molecular Roots Of Down Syndrome 3/24/2013

    What is it about the extra chromosome inherited in Down syndrome—chromosome 21—that alters brain and body development? Researchers have new evidence that points to a protein called sorting nexin 27, or SNX27.

  7. Selecta Biosciences And Sanofi Sign Global Collaboration To Develop Antigen-Specific Immunotherapies For Up To Three Allergy Indications Based On Selecta's Synthetic Vaccine Particle Technology 11/28/2012

    Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, recently announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

  8. Taiho Pharmaceutical Announces Start Of Global Phase III Clinical Trial In Metastatic Colorectal Cancer With Novel Antitumor Agent TAS-102 5/31/2012

    Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

  9. Cortex Biochem Awarded Patent 6/9/2005
    Cortex Biochem(TM) Inc., a global leader in developing magnetic particle technology and products used in genomic research and clinical diagnostics, announced it has received a U.S. patent for its MagaZorb(R) Nucleic Acid (DNA/RNA) Isolation and Purification System...
  10. Galapagos Announces GSK2586184 JAK1 Molecule Progresses To Phase 2 Studies 2/5/2013

    Galapagos NV (Euronext: GLPG) announced today that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.